Modern drug delivery systems for targeting the posterior segment of the Eye

Current Pharmaceutical Design

Volumn 21, Issue 42, 2015, Pages 6055-6069

  Peptu, Catalina A ^a   Popa, Marcel ^a,c   Savin, Corina ^a   Popa, Radu F ^b   Ochiuz, Lacramioara ^b  

^a GHEORGHE ASACHI TECHNICAL UNIVERSITY OF IASI   (Romania)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c ACADEMY OF ROMANIAN SCIENTISTS   (Romania)

Author keywords

Drug delivery; Hydrogels; Implants; Intravitreal; Liposomes; Micro and nanoparticles; Posterior segment of the eye; Sustained release

Indexed keywords

LIPOSOME; NANOCARRIER; NANOPARTICLE; DRUG; DRUG IMPLANT; HYDROGEL; MICROSPHERE;

AGE RELATED MACULAR DEGENERATION; ARTICLE; BIODEGRADABLE IMPLANT; CYTOMEGALOVIRUS RETINITIS; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG TARGETING; EYE DISEASE; HUMAN; HYDROGEL; IMPLANTATION; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; OCULAR BLOOD VESSEL; PERIOCULAR DRUG ADMINISTRATION; POSTERIOR EYE CHAMBER; PRIORITY JOURNAL; RETINITIS PIGMENTOSA; TOPICAL DRUG ADMINISTRATION; UVEITIS; ANIMAL; DRUG DESIGN; DRUG IMPLANT; EYE; EYE DISEASES; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG IMPLANTS; EYE; EYE DISEASES; HUMANS; HYDROGELS; MICROSPHERES; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS;

EID: 84957544822     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666151027151847     Document Type: Article

References (131)

1. Haghjou N, Soheilian M, Abdekhodaie MJ. Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res 2011; 6(4): 317-29.
2. Schultz C, Breaux J, Schentag J, Morck D. Drug delivery to the posterior segment of the eye through hydrogel contact lenses. Clin Exp Optom 2011; 94(2): 212-8.
3. Sheardown H, Mark Saltzman W. Novel Drug Delivery Systems for Posterior Segment Ocular Diseas, In Ocular Angiogenesis: Diseases, Mechanisms, and Therapeutics. Edited by: J. Tombran-Tink and CJ Barnstable © Humana Press Inc., Totowa, NJ 2006; 393-408.
4. Shah SS, Lori Vidal Denham, Jasmine R, et al. Drug delivery to the posterior segment of the eye for pharmacologic therapy. Expert Rev Ophthalmol 2010; 1; 5(1): 75-93.
5. Eljarrat-Binstock E, Pe’er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm Res 2010; 27(4): 530-43.
6. Huges PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev 2005; 57: 2010-32.
7. Loftsson T, Sigursson HH, Konrásdóttir F, Gιsladóttir S, Jansook P, Stefánsson E. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Invest Ophthalmol Vis Sci 2000; 41(5)
8. Kaur IP, Kakkar S. Nanotherapy for posterior eye diseases. J Control Release 2014; 193: 100-12.
9. Thrimawithana TR, Young S, Bunt CR, Greend C, Alany RG. Drug delivery to the posterior segment of the eye: challenges and opportunities. Drug Deliv Lett 2011, 1(1): 40-4
10. Loftsson T, Sigursson HH, Konrasdottir F, Gιsladóttir S, Jansook P, Stefansson E. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Pharmazie 2008; 63: 171-9.
11. Gaudana R, Ananathula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010; 12: 348-60.
12. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today 2008; 13(3-4): 144-51.
13. Herrero-Vanrell R, Cardillo JA. Ocular pharmacokinetic, drug bioavailability and intraocular drug delivery systems. In: Nguyen QD, Rodrigues EB, Farah ME, Mieler WF (eds.). China: Saunders Elsevier 2010; 60-66.
14. Cunha-Vaz JG. The blood-retinal barrier system. Basic concepts and clinical evaluation. Exp Eye Res 2004; 78(3): 715-21.
15. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 2008; 13: 135-143.
16. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci 2010; 51: 5403-20.
17. Ghate D and Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv 2006; 3: 275-87.
18. Mannerma E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 2006; 58: 1136-63.
19. Kiernan DF, Lim JI. Topical Drug Delivery for Posterior Segment Disease Novel formulations offer possibilities for efficacious therapies through topical routes. Retina Today 2010; 48: 48-54.
20. Sigurdsson HH, Konrásdóttir F, Loftsson T, Stefánsson E. Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. Acta Ophthalmol Scand 2007; 85: 598-602.
21. Van Wijngaarden P, Qureshi SH. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular agerelated macular degeneration: a review of current practice. Clin Exp Optom 2008; 91: 427-43.
22. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin®) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009; 93: 452-6.
23. Abrishami M, Ganavati SZ, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekeh-Nikouei B. Preparation, characterization, and in vivo evaluation of nanoliposomes encapsulated bevacizumab (avastin) for intravitreal administration. Retina Today 2009; 29: 699-703.
24. Sarao V, Veritti D, Boscia F, Lanzetta P. Intravitreal steroids for the treatment of retinal diseases. Sci World J 2014; 14: 1-14.
25. Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 2009; 28(1): 1-18
26. Birch DG, Liang FQ. Age-related macular degeneration: a target for nanotechnology derived medicines. Int J Nanomed 2007; 2(1): 65-77.
27. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
28. Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol 2004; 138: 1046-8.
29. Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 2007; 4: 371-88.
30. Cholkar K, Patel A, Vadlapudi AD, Mitra AK. Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery. Recent Pat Nanomed 2012; 2(2): 82-95.
31. Mains J, Wilson CG. The vitreous humor as a barrier to nanoparticle distribution. J Ocul Pharmacol Ther 2013; 29(2): 143-50.
32. Maurice D. Review: practical issues in intravitreal drug delivery. J Ocul Pharmacol Ther 2001; 17: 393-401.
33. Ranta VP, Mannermaa E, Lummepuro K, et al. Barrier analysis of periocular drug delivery to the posterior segment. J Control Release 2010; 148: 42-8.
34. Patel SR, Lin AS, Edelhauser HF, Prausnitz MR. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res 2011; 28(1): 166-76.
35. da Silva GR, Sílvia LF, Siqueira RC, Jorge R, da Silva ACJ. Implants as drug delivery devices for the treatment of eye diseases. Braz J Pharm Sci 2010; 46: 585-95.
36. Urtti A. Challanges and obstacles of ocular pharmacokinetics and drug delivery, Adv Drug Deliv Rev 2006; 58(11): 1131-5.
37. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis-Thirty-fourweek results of a multicenter randomized clinical study. Ophthalmology 2006; 113(6): 1020-7.
38. Guidetti B, Azema J, Malet-Martino M, Martino R. Delivery systems for the treatment of proliferative vitreoretinopathy: materials, devices and colloidal carriers. Curr Drug Deliv 2008; 5(1): 7-19.
39. Choonara YE, Pillay V, Danckwerts MP, Carmichael TR, DuToit LC. A Review of Implantable Intravitreal Drug Delivery Technologies for the Treatment of Posterior Segment Eye. Diseases. J Pharm Sci 2010; 99(5): 2219-39.
40. Bourges JL, Bloquela C, Thomasa A, et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 2006; 58: 1182-202.
41. Marx JL, Kapusta MA, Patel Sunil S, et al. Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis. Arch Ophthalmol 1996; 114: 815-20.
42. Montero JA, Ruiz-Moreno JM. Intravitreal inserts of steroids to treat diabetic macular edema. Curr Diabetes Rev 2009; 5(1): 26-32.
43. Lee SS, Robinson MR. Novel drug delivery systems for retinal diseases: a review. Ophthalmic Res 2009; 41(3): 124-35.
44. Thrimawithana TR, Young S, Bunt CR, Green C, Alany RG Drug delivery to the posterior segment of the eye. Drug Discov Today 2011; 16: 270-7.
45. Russel R. Bioerodable eye implant may help treat macular edema, Pharma Technol 2004; 28(18): 223.
46. Okabe J, Kimura H, Kunou N, Okabe K, Kato A, Ogura Y. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest Ophthalmol Vis Sci 2003; 44: 740-4.
47. Emerich DF, Thanos CG. NT-501: an ophthalmic implant of polymer encapsulated ciliary neurotrophic factor-producing cells. Curr Opin Mol Ther 2008; 10(5): 506-15.
48. Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA. Ocular pharmacokineticsof fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004; 20(3): 269-75.
49. Kim YC, Chiang B, Wu X, Prausnitz MR. Ocular delivery of macromolecules. J Control Release 2014; 190: 172-81.
50. Yasukawa T, Ogura Y, Sakurai E, Tabata Y, Kimura H. Intraocular sustained drug delivery using implantable polymeric devices. Adv Drug Deliv Rev 2005; 57(14): 2033-46.
51. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci 2000; 41(5): 1186-91.
52. Sanborn GE, Anand R, Torti RE, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Arch Ophthalmol 1992; 110(2): 188-95.
53. Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable Implants for Sustained Drug Release in the Eye. Pharm Res 2010; 27(10): 2043-53.
54. Okabe K, Kimura H, Okabe J, Kato A, N Kunou, Ogura Y. Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest Ophthalmol Vis Sci 2003; 44(6): 2702-7.
55. Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000; 107(11): 2024-33.
56. Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis, Retina 2000; 20(4): 402-3.
57. Yang CS, Khawly JA, Hainsworth DP, et al. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 1998; 116(1): 69-77.
58. Mikhail M, Sallam A. Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye. Med Hypothesis Discov Innov Ophthalmol 2013; 2(4): 113-20.
59. Jaffe GJ. Reimplantation of a fluocinoloneacetonide sustained drug delivery implant for chronic uveitis. Am J Ophthalmol 2008; 145(4): 667-75.
60. Sanford M. Fluocinolone acetonide intravitreal implant (Iluvien®). In diabetic macular oedema. Drugs 2013; 73(2): 187-93.
61. Dugel PU, Eliott D, Cantrill HL, Mahmoud T, Avery R, Erickson SR. I-vation TM TA: 24-month clinical results of the phase I safety and preliminary efficacy study. Proceedings of the Association for Research in Vision and Ophthalmology Annual Meeting. Fort Lauderdale, Fla, USA, 2009.
62. Carcaboso AM, Chiappetta DA, Opezzo JA, et al. Episcleral Implants for Topotecan Delivery to the Posterior Segment of the Eye. Invest Ophthalmol Vis Sci 2010; 51(4): 2126-34.
63. Nagai N, Kaji H, Onami H, et al. A polymeric device for controlled transscleral multi-drug delivery to the posterior segment of the eye. Acta Biomater 2014; 10(2): 680-7.
64. Conway BR. Recent patents on ocular drug delivery systems. Recent Pat Drug Deliv Formul 2008; 2(1): 1-8.
65. Yasin MN, Svirskis D, Seyfoddin A, Rupenthal ID. Implants for drug delivery to the posterior segment of the eye: A focus on stimuli-responsive and tunable release systems. J Control Release 2014; 196: 208-21.
66. Yasukawa T, Kimura MDH, Tabat Y, Ogura Y. Biodegradable scleral plugs for vitreoretinal drug delivery. Adv Drug Deliv Rev 2001; 52(1): 25-36.
67. Avitabile T, Marano F, Castiglione F, et al. Biocompatibility and biodegradation of intravitreal hyaluronan implants in rabbits. Biomaterials 2001; 22(3): 195-200.
68. Choonara YE, Pillay V, Carmichael T, Danckwerts MP. Studies on a novel doughnut-shaped mini tablet for intraocular drug delivery. AAPS PharmSciTech 2007; 8(4): E118.
69. Hunter RS, Lobo AM. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol 2011; 5: 1613-21.
70. Siddique SS, Shah R, Suelves AM, Foster CS. Road to remission: a comprehensive review of therapy in uveitis. Expert Opin Investig Drugs 2011; 20(11): 1497-515.
71. Cabrera M, Yeh S, Albini TA. Sustained-Release Corticosteroid Options. Hindawi Publishing Corporation, J Ophthalmol 2014; 2014: 164692.
72. Wang J, Jiang A, Joshi M, Christoforidis J. Drug delivery implants in the treatment of vitreous inflammation. Mediat. Inflamm 2013; ID 780634.
73. Guse C, Koennings S, Maschke A, et al. Biocompatible and erosion behavior of implants made of triglycerides and blends with cholesterol and phospholipids. Int J Pharm 2006; 314(2): 153-60.
74. Tamaddon L, Mostafavi A, Riazi-Esfahani M, et al. Development, characterization and biocompatibility evaluatyion of intravitreal lipid implant. Jundishapur J Nat Pharm Prod 2014; 9(2): e16414.
75. Kuno N, Fujii S. Biodegradable intraocular therapies for retinal disorders: progress to date. Drugs Aging 2010; 27(2): 117-34.
76. Kuno N, Fujii S. Ocular drug delivery systems for the posterior segment: a review. Retina Today 2012; 5: 54-59.
77. Pirmoradi FN, Jackson JK, Burt HM, Chiao M. On-demand controlled release of docetaxel from a battery-less. Lab Chip 2011; 11(16): 2744-52.
78. Su YC, Lin LW. A water-powered micro drug delivery system. J. Microelectromech. Syst 2004; 13: 75-8.
79. Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev 2002; 54(1): 3-12.
80. Kang Derwent JJ and Mieler WF. Thermoresponsie hydrogels as new ocular drug delivery platform to the posterior segment of the eye. Trans Am Ophthalmol Soc 2008; 106: 206-14.
81. Kompella UB, Kadam RS, Lee VHL. Recent advances in ophthalmic drug delivery. Ther Deliv 2010; 1(3): 435-56.
82. Mazumder MA, Fitzpatrick SD, Muirhead B, Sheardown H. Celladhesive thermogelling PNIPAAm/hyaluronic acid cell delivery hydrogels for potential application as minimally invasive retinal therapeutics. J Biomed Mater Res A 2012; 100(7): 1877-87.
83. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol 2013; 2(2): 47-64.
84. Qian Y, Wang F, Li R, Zhang Q, Xu Q. Preparation and evaluation of in situ gelling ophthalmic drug delivery system for methazolamide. Drug Dev Ind Pharm 2010; 36(11): 1340-7.
85. Bonacucina G, Cespi M, Mencarelli G, Giorgioni G, Palmieri GF. Thermosensitive Self-Assembling Block Copolymers as Drug Delivery Systems. Polymers 2011; 3(2): 779-811
86. Chen X, Li X, Zhou Y, et al. Chitosan-based thermosensitive hydrogel as a promising ocular drug delivery system: preparation, characterization, and in vivo evaluation. J Biomater Appl 2012; 27(4): 391-402.
87. Rajoria G, Gupta A. In Situ Gelling System: A Novel Approach for Ocular Drug Delivery. AJPTR 2012; (2): 24-53.
88. Gao Y, Sun Y, Ren F, Gao S. PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate. Drug Dev Ind Pharm 2010; 36(10): 1131-8.
89. Pahuja P, Arora S, Pawar P. Ocular drug delivery system: a reference to natural polymers. Expert Opin Drug Deliv 2012; 9(7): 837-61.
90. Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advances in ocular drugdelivery. Drug Dev Ind Pharm 2013; 39: 1599-617.
91. Wang CH, Hwang YS, Chiang PR, Shen CR, Hong WH, Hsiue GH. Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel. Biomacromolecules 2012; 13(1): 40-8.
92. Lovett ML, Wang X, Yucel T, et al. Silk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics. Eur J Pharm Biopharm 2015 Jan 12. pii: S0939-6411(15)00004-1.
93. Rauck BM, Friberg TR, Medina Mendez CA, et al. Biocompatible Reverse Thermal Gel Sustains the Release of Intravitreal Bevacizumab In Vivo. Invest Ophthalmol Vis Sci 2014; 55(1): 469-76.
94. Wang CH, Hwang YS, Chiang PR, Shen CR, Hong WH, Hsiue GH. Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel. Biomacromolecules 2012; 13(1): 40-8.
95. Hwang YS, Chiang PR, Hong WH, et al. Study In Vivo Intraocular Biocompatibility of In Situ Gelation Hydrogels: Poly(2-Ethyl Oxazoline)-Block-Poly(ε-Caprolactone)-Block-Poly(2-Ethyl Oxazoline) Copolymer. Matrigel and Pluronic F127, PLoS One 2013; 8(7): e67495.
96. Rieke ER, Amaral J, Becerra SP, Lutz RJ. Sustained subconjunctival protein delivery using a thermosetting gel delivery system. J Ocul Pharmacol Ther 2010; 26(1): 55-64.
97. Zhang XZ, Chu CC. Fabrication and characterization of microgelimpregnated, thermosensitive PNIPAAm hydrogels. Polymer 2005; 46: 9664-73.
98. Kang Derwent JJ, Mieler WF. Thermoresponsive hydrogel as a new ocvular drug delivery platform to the posterior segment of the eye. Trans Am Ophthalmol Soc 2008; 106: 206-13.
99. Turturro SB, Guthrie MJ, Appel AA, et al. The effects of crosslinked thermo-responsive PNIPAAm-based hydrogel injection on retinal function. Biomaterials 2011; 32(14): 3620-6.
100. Misra GP, Singh RS, Aleman TS, Jacobson SG, Gardner TW, Lowe TL. Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina. Biomaterials 2009; 30(33): 6541-7.
101. Prestwich GD. Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative medicine. J Control Release 2011; 155(2): 193-9.
102. Prestwich GD, Erickson IE, Zarembinski TI, West M, Tew WP. The translational imperative: making cell therapy simple and effective. Acta Biomater 2012; 8(12): 4200-7.
103. Liu Y, Wang R, Zarembinski TI, et al. The application of hyaluronic acid hydrogels to retinal progenitor cell transplantation. Tissue Eng Part A 2013; 19(1-2): 135-42.
104. Zarembinski TI, Doty NJ, Erickson IE, Srinivas R, Wirostko BM, Tew WP. Thiolated hyaluronan-based hydrogels crosslinked using oxidized glutathione: An injectable matrix designed for ophthalmic applications. Acta Biomater 2014; 10(1): 94-103.
105. Christie JG, Kompella UB. Ophthalmic light sensitive nanocarrier systems. Drug Discov Today 2008; 13(3-4): 124-34.
106. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13(1): 238-252.
107. Ebrahim S, Peyman GA, Lee PJ. Applications of Liposomes in Ophthalmology. Surv Ophthalmol 2005; 50(2): 167-82.
108. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomed 2012; 7: 49-60.
109. Gupta SK, Agarwal R, Srivastava S. Textbook on clinical ocular pharmacology and therapeutics. JP Medical Ltd 2014; 65-84.
110. Souto EB, Doktorovova S, Gonzalez-Mira E, Egea MA, Garcia ML. Feasibility of lipid nanoparticles for ocular delivery of antiinflammatory drugs. Curr Eye Res 2010; 35(7): 537-52.
111. Liu CH, Chiu HC, Wu WC, Sahoo SL, Hsu CY. Novel Lutein Loaded Lipid Nanoparticles on Porcine Corneal Distribution. J Ophthalmol 2014; 2014: 304694.
112. Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008; 355(1-2): 307-13.
113. Hao J, Wang X, Bi Y, et al. Fabrication of a composite system combining solid lipid nanoparticles and thermosensitive hydrogel for challenging ophthalmic drug delivery. Colloids Surf B Biointerfaces 2014; 114: 111-20.
114. Araújo J, Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int J Pharm 2010; 393(1-2): 167-75.
115. Sasaki H, Karasawa K, Hironaka K, Tahara K, Tozuka Y, Takeuchi H. Retinal drug delivery using eyedrop preparations of poly-Llysine-modified Liposomes. Eur J Pharm Biopharm 2013; 83(3): 364-9.
116. Lajunen T, Hisazumi K, Kanazawa T, et al. Topical drug delivery to retinal pigment epithelium with microfluidizer produced small liposomes. Eur J Pharm Sci 2014; 62: 23-32.
117. Amrite AC, Kompella UB. In: Nanoparticles for Ocular Drug Delivery in Nanoparticle Technology for Drug Delivery edited by Gupta RB and Kompella UB, Taylor & Francis Group, 2006, Chapter 11.
118. Suri S, Ruan G, Winter J, Schmidt CE. Microparticles and Nanoparticles. In Biomaterials Science An Introduction to Materials in Medicine. Third Edition, Elsevier 2013, Chapter I.2.19, ISBN: 978-0-12-374626-9; 360-88.
119. Mitra AK. Treatise on Ocular Drug Delivery. Chapter 5-Biodegradable polymers for ophthalmic application. Bentham Science Publishers 2013; 96-114.
120. de Campos AM, Diebold Y, Carvalho EL, Sánchez A, Alonso MJ. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res 2004; 21(5): 803-10.
121. Aȿιk MD, Uğurlu N, Yülek F, Tuncer S, Türk M, Baki ED. Ketorolac Tromethamine Loaded Chitosan Nanoparticles as a Nanotherapeutic System for Ocular Diseases. Hacettepe J Biol Chem 2013, 41 (1): 81-6.
122. Rajendran NN, Natrajan R, Kumar RS, Selvaraj S. Acyclovirloaded chitosan nanoparticles for ocular delivery. Asian J Pharmacol 2010; 4 (4): 220-6.
123. Silva NC, Silva S, Sarmento B, Pintado M. Chitosan nanoparticles for daptomycin delivery in ocular treatment of bacterial endophthalmitis. Drug Deliv 2015; 22: 1-9.
124. Katiyar S, Pandit J, Mondal RS, et al. In situ gelling dorzolamide loaded chitosan nanoparticles for the treatment of glaucoma. Carbohydr Polym 2014; 102: 117-24.
125. Tsukamoto T, Hironaka K, Fujisawa T, et al. Preparation of bromfenac-loaded liposomes modified with chitosan for ophthalmic drug delivery and evaluation of physicochemical properties and drug release profile. Asian J Pharm Sci 2013; 8: 104-9.
126. Nagarwal RC, Kumar R, Pandit JK. Chitosan coated sodium alginate-chitosan nanoparticles loaded with 5-FU for ocular delivery: In vitro characterization and in vivo study in rabbit eye. Eur J Pharm Sci 2012; 47(4): 678-85.
127. Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 2008; 68(3): 513-25.
128. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation. J Drug Target 2010; 18(4): 292-302.
129. Qian L, Zheng J, Wang K, et al. Cationic coreshell nanoparticles with carmustine contained within O6-benzylguanine shell for glioma therapy. Biomaterials 2013; 34(35): 8968-78.
130. Gomez-Gaete C, Tsapis N, Besnard M, Bochot A, Fattal E. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm 2007; 331: 153-9.
131. Janoria KG, Mitra AK. Effect of lactide/glycolide ratio on the in vitro release of ganciclovir and its lipophilic prodrug (GCVmonobutyrate) from PLGA microspheres. Int J Pharm 2007; 338(1-2): 133-41.